← Back to Search

Vasodilator

iNOMAX for Acute Respiratory Distress Syndrome

Q: Are there opportunities for patient enrollment in the ongoing recruitment phase of this clinical trial?

<p>Information from clinicaltrials.gov indicates that the current trial is not actively enrolling participants. Although it was initially shared on 2/1/2024 and last revised on 1/31/2024, there are currently 939 alternative trials open for recruitment.</p>

Phase < 1

Waitlist Available

Led By Yuri Matusov, MD

Research Sponsored by Yuri Matusov

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥ 18 years

Mechanically ventilated

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 4 days

Awards & highlights

Study Summary

"This trial is studying the use of inhaled nitric oxide for patients who develop pulmonary hypertension during Acute Respiratory Distress Syndrome. The goal is to see if giving nitric oxide early in the

Who is the study for?

This trial is for patients with ARDS who are starting to show signs of high blood pressure in the lungs. It's open to those who haven't yet received treatment for this specific complication.Check my eligibility

What is being tested?

The study tests if inhaling nitric oxide (iNO) early on can help manage increased lung blood pressure and improve overall health in ARDS patients.See study design

What are the potential side effects?

Inhaled nitric oxide may cause headaches, dizziness, or a rise in methemoglobin levels which reduces oxygen delivery by blood.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I am on a mechanical ventilator.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 4 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 4 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 4 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Determining improvement in pulmonary artery pressure in response to iNO

Determining improvement in right ventricular fractional area change in response to iNO

Determining improvement in tricuspid annular plane systolic excursion in response to iNO

Secondary outcome measures

Improvement in serum creatinine in response to iNO

Improvement in urine output in response to iNO

Trial Design

1Treatment groups

Experimental Treatment

Group I: iNOMAXExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Nitric Oxide

2004

Completed Phase 4

~1280

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Yuri MatusovLead Sponsor

MallinckrodtIndustry Sponsor

201 Previous Clinical Trials

16,208 Total Patients Enrolled

Yuri Matusov, MDPrincipal InvestigatorCedars-Sinai Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there opportunities for patient enrollment in the ongoing recruitment phase of this clinical trial?

"Information from clinicaltrials.gov indicates that the current trial is not actively enrolling participants. Although it was initially shared on 2/1/2024 and last revised on 1/31/2024, there are currently 939 alternative trials open for recruitment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension

Yuri Matusov 2024. "Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06249633.

All > Pulmonary Hypertension > Ards